Company Filing History:
Years Active: 2019
Title: David Emlyn Parfitt: Innovator in Infertility Assessment
Introduction
David Emlyn Parfitt is a notable inventor based in New York, NY, recognized for his contributions to the field of reproductive health. He holds a patent that focuses on methods and systems for assessing infertility and related pathologies. His innovative work aims to enhance the understanding and treatment of infertility, particularly for conditions such as endometriosis.
Latest Patents
Parfitt's patent, titled "Methods and systems for assessing infertility and related pathologies," provides a novel approach to assessing infertility issues. The methods outlined include determining levels of various transcripts in samples obtained from patients suspected of endometriosis. By identifying transcript levels that correspond to specific patterns in the uterine cycle, the invention characterizes endometriosis based on these levels. Furthermore, it includes methods to assess age-associated increases in aneuploidy rates linked to FSH levels and evaluates IVF success rates in obese patients with PCOS.
Career Highlights
David Emlyn Parfitt is currently affiliated with Celmatix, Inc., where he continues to work on advancing reproductive health solutions. His work plays a crucial role in developing innovative tools for fertility assessments, aiming to improve patient outcomes in infertility treatments.
Collaborations
At Celmatix, Parfitt collaborates with notable colleagues, including Piraye Yurttas Beim and Michael Elashoff. These partnerships enhance the research and development efforts in the field of women's health and fertility, pushing boundaries and innovating solutions for patients.
Conclusion
David Emlyn Parfitt exemplifies the impact of innovative thinking in the field of infertility assessment. His patent not only opens new avenues for understanding reproductive challenges but also signifies the importance of collaboration in scientific research. As he continues to work with skilled professionals at Celmatix, the advancements in this field may lead to significant improvements in infertility treatments and patient care.